A dose escalation study designed to demonstrate the safety, tolerability and efficacy of the fully human anti-TNF antibody, D2E7, given in combination with methotrexate (MTX) in patients with active RA.

被引：0
|
作者：
Weisman, M
Keystone, E
Paulus, H
Weinblatt, M
Furst, D
Moreland, L
Velagapudi, R
Fischkoff, S
Chartash, E
机构：
来源：
ARTHRITIS AND RHEUMATISM | 2000年 / 43卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1948
引用
收藏
页码：S391 / S391
页数：1
相关论文
共 40 条
  • [21] A fully human anti-TNF mAb adalimumab (D2E7) induces caspase-dependent apoptosis of human peripheral blood monocytes and T cells
    Shen, C
    Maerten, P
    Van Assche, G
    Geboes, K
    Rutgeerts, P
    Ceuppens, J
    GASTROENTEROLOGY, 2004, 126 (04) : A153 - A153
  • [22] Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis:: a 12 week, phase II study
    van de Putte, LBA
    Rau, R
    Breedveld, FC
    Kalden, JR
    Malaise, MG
    van Riel, PLCM
    Schattenkirchner, M
    Emery, P
    Burmester, GR
    Zeidler, H
    Moutsopoulos, HM
    Beck, K
    Kupper, H
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (12) : 1168 - 1177
  • [23] Randomized, Double-blind, Placebo-controlled, Comparative Study of Human Anti-TNF Antibody Adalimumab in Combination with Methotrexate and Methotrexate Alone in Taiwanese Patients with Active Rheumatoid Arthritis
    Chen, Der-Yuan
    Chou, Show-Jan
    Hsieh, Tsu-Yi
    Chen, Yi-Hsing
    Chen, Hsin-Hua
    Hsieh, Chia-Wei
    Lan, Joung-Liang
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2009, 108 (04) : 310 - 319
  • [24] Long-term treatment with the fully human anti-TNF-antibody D2E7 slows radio-graphic disease progression in rheumatoid arthritis.
    Rau, R
    Herborn, G
    Sander, O
    van de Putte, LBA
    van Riel, PLC
    den Broeder, A
    Schattenkirchner, M
    Wastlhuber, J
    Rihl, M
    Fenner, H
    Kempeni, J
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S400 - S400
  • [25] In vitro and in vivo comparison of adalimumab (D2E7), a fully human Anti-TNF-α monoclonal antibody, expressed in transfected CHO cells versus transgenic goats.
    Kaymakçalan, Z
    Sakorafas, P
    Xiong, L
    Beam, C
    Kalghatgi, L
    Stanley, K
    Avgerinos, G
    Salfeld, J
    CLINICAL IMMUNOLOGY, 2002, 103 (03) : S103 - S103
  • [26] TNF blockade by the fully human monoclonal antibody, adalimumab (D2E7), in the ARMADA trial results in decreases in serum matrix metalloproteinase (MMP) levels along with impressive clinical improvement in refractory RA patients.
    Furst, D
    Keystone, E
    Weinblatt, M
    Kavanaugh, A
    Weisman, M
    Fischkoff, S
    Chartash, E
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S215 - S215
  • [27] Golimumab, a human Anti-TNFα monoclonal antibody, injected every 4 weeks:: Efficacy & safety in RA patients previously treated with anti-TNFa agents (GO-A-FTER study)
    Smolen, J.
    Kay, J.
    Doyle, M. K.
    Landewe, R.
    Matteson, E. L.
    Willenhaupt, J.
    Gaylis, N.
    Murphy, F.
    Neal, J.
    Zhou, Y.
    Visvanathan, S.
    Hsia, E. C.
    Rahman, M. U.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S523 - S524
  • [28] Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors
    Shitara, Kohei
    Satoh, Taroh
    Iwasa, Satoru
    Yamaguchi, Kensei
    Muro, Kei
    Komatsu, Yoshito
    Nishina, Tomohiro
    Esaki, Taito
    Hasegawa, Jun
    Kakurai, Yasuyuki
    Kamiyama, Emi
    Nakata, Tomoko
    Nakamura, Kota
    Sakaki, Hayato
    Hyodo, Ichinosuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [29] EFFICACY AND SAFETY OF ABBV-3373, A NOVEL ANTI-TNF GLUCOCORTICOID RECEPTOR MODULATOR ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY: A PHASE 2A PROOF OF CONCEPT STUDY
    Buttgereit, F.
    Aelion, J.
    Rojkovich, B.
    Zubrzycka-Sienkiewicz, A.
    Radstake, T.
    Chen, S.
    Arikan, D.
    Kupper, H.
    Amital, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 64 - 64
  • [30] Efficacy and safety of anti-fractalkine monoclonal antibody, E6011, in patients with Crohn's disease who had lost response to anti-TNFα agents: A multicentre, open-label, Phase 1/2 study
    Matsuoka, K.
    Naganuma, M.
    Tanida, S.
    Kitamura, K.
    Matsui, T.
    Arai, M.
    Fujiya, M.
    Horiki, N.
    Nebiki, H.
    Kinjo, F.
    Miyazaki, T.
    Matsumoto, T.
    Esaki, M.
    Mitsuyama, K.
    Saruta, M.
    Ido, A.
    Hojo, S.
    Takenaka, O.
    Oketani, K.
    Imai, T.
    Tsubouchi, H.
    Hibi, T.
    Kanai, T.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S70 - S70
1234